Fig. 8

ELISA-based determination of plasma markers involved in lung pathobiology. a suppression of the pro-inflammatory marker IL-1β by esomeprazole; b inhibition of circulating MMP7 by esomeprazole; c increased level of the lung repair-associated protein CHI3L1 by esomeprazole; d higher levels of the cytoprotective and effector molecule for HO1, bilirubin, by esomeprazole treatment; e increased circulating level of ADMA and f reduced plasma NO upon esomeprazole treatment. *p < 0.05 compared to vehicle. IL-1β interleukin 1 beta, MMP7 matrix metalloproteinase-7, CHI3L1 chitinase 3-like 1, HO1 heme oxygenase-1, ADMA asymmetric dimethylarginine, NO nitric oxide.